Tropomodulin 1 expression driven by NF-κB enhances breast cancer growth

Cancer Research

Volumn 75, Issue 1, 2015, Pages 62-72

  Ito Kureha, Taku ^a,b   Koshikawa, Naohiko ^a   Yamamoto, Mizuki ^c   Semba, Kentaro ^c   Yamaguchi, Noritaka ^d   Yamamoto, Tadashi ^b   Seiki, Motoharu ^e   Inoue, Jun Ichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY   (Japan)

^c WASEDA UNIVERSITY   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e KOCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CHOLESTEROL 25 HYDROXYLASE; CLAUDIN; COLLAGEN TYPE 1; COLLAGENASE 3; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OXYGENASE; RETROVIRUS VECTOR; TROPOMODULIN; TROPOMODULIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANIN 2; TMOD1 PROTEIN, HUMAN;

ACTIN FILAMENT; ADENOVIRUS INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIRC3 GENE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELL PROLIFERATION; CH25H GENE; CHROMOSOME 15; CONTROLLED STUDY; DEPOLYMERIZATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; GENE; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RELB GENE; TMOD1 GENE; TNFAIP3 GENE; TRANSCRIPTION ELONGATION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; VNN2 GENE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG SCREENING; FEMALE; GENETICS; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TROPOMODULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920518153     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3455     Document Type: Article

References (45)

1. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
2. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007;7:659-72.
3. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007;8:R76.
4. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
5. Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis- Filho JS, et al. Prognostic value of proliferation assay in the luminal, HER2- positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res 2012;14:R3.
6. Inoue J, Gohda J, Akiyama T, Semba K. NF-κB activation in development and progression of cancer. Cancer Sci 2007;98:268-74.
7. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 2008;132:344-62.
8. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006;2006:re13.
9. Sun SC. Controlling the fate of NIK: a central stage in noncanonical NF-κB signaling. Sci Signal 2010;3:pe18.
10. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-6.
11. Yamaguchi N, Ito T, Azuma S, Ito E, Honma R, Yanagisawa Y, et al. Constitutive activation of nuclear factor-κB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci 2009;100:1668-74.
12. Yamamoto M, Ito T, Shimizu T, Ishida T, Semba K, Watanabe S, et al. Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer. Cancer Sci 2010;101:2391-7.
13. Kostyukova AS. Tropomodulins and tropomodulin/tropomyosin interactions. Cell Mol Life Sci 2008;65:563-9.
14. Gregorio CC, Weber A, Bondad M, Pennise CR, Fowler VM. Requirement of pointed-end capping by tropomodulin to maintain actin filament length in embryonic chick cardiac myocytes. Nature 1995;377:83-6.
15. Tsukada T, Kotlyanskaya L, Huynh R, Desai B, Novak SM, Kajava AV, et al. Identification of residues within tropomodulin-1 responsible for its localization at the pointed ends of the actin filaments in cardiac myocytes. J Biol Chem 2011;286:2194-204.
16. Ito E, Honma R, Yanagisawa Y, Imai J, Azuma S, Oyama T, et al. Novel clusters of highly expressed genes accompany genomic amplification in breast cancers. FEBS Lett 2007;581:3909-14.
17. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-5.
18. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human IκBα on serines 32 and 36 controls IκBα proteolysis and NF-κB activation in response to diverse stimuli. EMBO J 1995;14:2876-83.
19. Fowler VM. Identification and purification of a novel Mr 43,000 tropomyosin- binding protein from human erythrocyte membranes. J Biol Chem 1987;262:12792-800.
20. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007;130:601-10.
21. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005;5:675-88.
22. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
23. Lemaitre V, D'Armiento J. Matrix metalloproteinases in development and disease. Birth Defects Res C Embryo Today 2006;78:1-10.
24. Kasaoka T, Nishiyama H, Okada M, Nakajima M. Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models. Clin Exp Metastasis 2008;25:827-34.
25. Hotary KB, Yana I, Sabeh F, Li XY, Holmbeck K, Birkedal-Hansen H, et al. Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and-independent processes. J Exp Med 2002;195:295-308.
26. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
27. Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, Lopez-Otin C. Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors. APMIS 1999;107:45-53.
28. Borden P, Solymar D, Sucharczuk A, Lindman B, Cannon P, Heller RA. Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes. J Biol Chem 1996;271:23577-81.
29. Uria JA, Jimenez MG, Balbin M, Freije JM, Lopez-Otin C. Differential effects of transforming growth factor-b on the expression of collagenase-1 and collagenase-3 in human fi broblasts. J Biol Chem 1998;273:9769-77.
30. Yun K, Im SH. Transcriptional regulation of MMP13 by Lef1 in chondrocytes. Biochem Biophys Res Commun 2007;364:1009-14.
31. Nathke I. Cytoskeleton out of the cupboard: colon cancer and cytoskeletal changes induced by loss of APC. Nat Rev Cancer 2006;6:967-74.
32. Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006;206:1-8.
33. Taniwaki K, Fukamachi H, Komori K, Ohtake Y, Nonaka T, Sakamoto T, et al. Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res 2007;67:4311-9.
34. Yana I, Seiki M. MT-MMPs play pivotal roles in cancer dissemination. Clin Exp Metastasis 2002;19:209-15.
35. Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996;271:17124-31.
36. Chang HJ, Yang MJ, Yang YH, Hou MF, Hsueh EJ, Lin SR. MMP13 is potentially a new tumor marker for breast cancer diagnosis. Oncol Rep 2009;22:1119-27.
37. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009;9:20.
38. Hatsell S, Rowlands T, Hiremath M, Cowin P. β-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 2003;8:145-58.
39. Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004;9:119-31.
40. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 2010;176:2911-20.
41. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, daCosta LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
42. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, et al. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999;96:5522-7.
43. Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, Garrett E, et al. b-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res 2003;63:3145-53.
44. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, et al. The metalloproteinase matrilysin is a target of b-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-91.
45. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. b-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999;155:1033-8.